Jun 15, 2020
Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting
Jan 09, 2020
Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors
Nov 20, 2019
Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine
Oct 17, 2019
Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors
Sep 05, 2019
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
Sep 03, 2019
Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
Jun 26, 2019
Impel NeuroPharma Appoints John Leaman as Chief Financial Officer
Apr 30, 2019
Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting
Feb 19, 2019
Impel NeuroPharma Appoints Jennifer L. Berman As Vice President Of Marketing
Jan 06, 2019
Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Aug 29, 2018
Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Jun 26, 2018
Impel NeuroPharma To Present New Data On INP104 For Treatment Of Acute Migraine At 2018 Annual American Headache Society Meeting
Jun 22, 2018
Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine
May 31, 2018
Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson's Disease OFF Episodes
Feb 07, 2018
Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache
Oct 31, 2017
Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache